These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36519539)

  • 21. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
    Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
    Vaschetto R; Navalesi P; Clemente N; Boggio E; Valsecchi S; Olivieri C; Soluri MF; Kroumova V; Fonio P; Dinatale C; Borrè S; Fortina G; Umberto D; Della Corte F; Chiocchetti A
    Minerva Anestesiol; 2015 Feb; 81(2):157-65. PubMed ID: 24994498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
    Dowsett J; Ferkingstad E; Rasmussen LJH; Thørner LW; Magnússon MK; Sugden K; Thorleifsson G; Frigge M; Burgdorf KS; Ostrowski SR; Sørensen E; Erikstrup C; Pedersen OB; Hansen TF; Banasik K; Brunak S; ; Tragante V; Lund SH; Stefansdottir L; Gunnarson B; Poulton R; Arseneault L; Caspi A; Moffitt TE; Gudbjartsson D; Eugen-Olsen J; Stefánsson H; Stefánsson K; Ullum H
    Commun Biol; 2021 Jun; 4(1):655. PubMed ID: 34079037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
    Rasmussen LJH; Petersen JEV; Eugen-Olsen J
    Front Immunol; 2021; 12():780641. PubMed ID: 34925360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
    Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
    Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
    Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
    J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
    Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
    Isola G; Polizzi A; Alibrandi A; Williams RC; Leonardi R
    J Periodontol; 2021 Jun; 92(6):896-906. PubMed ID: 33091149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of plasma soluble urokinase plasminogen activator receptor (SuPAR) levels in ulcerative colitis.
    Erbak Yılmaz H; Aksun S; Günay S; Elmalı F; Çekiç C
    Arab J Gastroenterol; 2023 Aug; 24(3):175-179. PubMed ID: 37045728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children.
    Kosecik M; Dervisoglu P; Koroglu M; Isguven P; Elmas B; Demiray T; Altindis M
    Int J Cardiol; 2017 Feb; 228():158-161. PubMed ID: 27865178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation.
    Koh AS; Velmurugan B; Gao F; Tan RS; Wong JI; Teo LLY; Keng BMH; Chua SJM; Yuan JM; Koh WP; Cheung C
    BMC Geriatr; 2017 Nov; 17(1):275. PubMed ID: 29179674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
    Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
    J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
    Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
    Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble urokinase plasminogen activator receptor (suPAR) promotes atherosclerosis.
    Drueke TB; Massy ZA
    Kidney Int; 2023 Mar; 103(3):451-454. PubMed ID: 36549362
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
    Chenevier-Gobeaux C; Lemarechal H; Doumenc B; Peschanski N; Claessens YE; Borderie D; Ray P
    Clin Biochem; 2021 Jun; 92():19-24. PubMed ID: 33662350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of clinical utility and predictive potential of pre-chemotherapy soluble urokinase plasminogen activator receptor: Observational single center study.
    Beleva E; Stoencheva S; Deneva T; Nenova I; Grudeva-Popova Z
    Biomol Biomed; 2023 Mar; 23(2):287-297. PubMed ID: 36124441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
    Ishikawa H; Izumiya Y; Shibata A; Ichikawa Y; Yamaguchi T; Yamaguchi Y; Kitada R; Iwata S; Ehara S; Tomita S; Hanatani A; Yoshiyama M
    Heart Vessels; 2020 May; 35(5):681-688. PubMed ID: 31741050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
    Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
    J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.